The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Myotonic Dystrophy Type 1 (DM1) Market Research Report 2025
Synopsis
The global Myotonic Dystrophy Type 1 (DM1) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Myotonic Dystrophy Type 1 (DM1), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myotonic Dystrophy Type 1 (DM1).
Report Scope
The Myotonic Dystrophy Type 1 (DM1) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Myotonic Dystrophy Type 1 (DM1) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Myotonic Dystrophy Type 1 (DM1) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Dyne
Audentes
Pfizer
Vertex
PepGen
NeuBase Therapeutics
Lupin
AMO Pharma
Expansion Therapeutics
Harmony Biosciences
Segment by Type
Exondys
Emflaza
Translarna
Segment by Application
Hospitals
Clinics
Home Care
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Myotonic Dystrophy Type 1 (DM1) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Myotonic Dystrophy Type 1 (DM1) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Myotonic Dystrophy Type 1 (DM1), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myotonic Dystrophy Type 1 (DM1).
Report Scope
The Myotonic Dystrophy Type 1 (DM1) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Myotonic Dystrophy Type 1 (DM1) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Myotonic Dystrophy Type 1 (DM1) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Dyne
Audentes
Pfizer
Vertex
PepGen
NeuBase Therapeutics
Lupin
AMO Pharma
Expansion Therapeutics
Harmony Biosciences
Segment by Type
Exondys
Emflaza
Translarna
Segment by Application
Hospitals
Clinics
Home Care
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Myotonic Dystrophy Type 1 (DM1) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Exondys
1.2.3 Emflaza
1.2.4 Translarna
1.3 Market by Application
1.3.1 Global Myotonic Dystrophy Type 1 (DM1) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Myotonic Dystrophy Type 1 (DM1) Market Perspective (2019-2030)
2.2 Myotonic Dystrophy Type 1 (DM1) Growth Trends by Region
2.2.1 Global Myotonic Dystrophy Type 1 (DM1) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Myotonic Dystrophy Type 1 (DM1) Historic Market Size by Region (2019-2024)
2.2.3 Myotonic Dystrophy Type 1 (DM1) Forecasted Market Size by Region (2025-2030)
2.3 Myotonic Dystrophy Type 1 (DM1) Market Dynamics
2.3.1 Myotonic Dystrophy Type 1 (DM1) Industry Trends
2.3.2 Myotonic Dystrophy Type 1 (DM1) Market Drivers
2.3.3 Myotonic Dystrophy Type 1 (DM1) Market Challenges
2.3.4 Myotonic Dystrophy Type 1 (DM1) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myotonic Dystrophy Type 1 (DM1) Players by Revenue
3.1.1 Global Top Myotonic Dystrophy Type 1 (DM1) Players by Revenue (2019-2024)
3.1.2 Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Players (2019-2024)
3.2 Global Myotonic Dystrophy Type 1 (DM1) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Myotonic Dystrophy Type 1 (DM1) Revenue
3.4 Global Myotonic Dystrophy Type 1 (DM1) Market Concentration Ratio
3.4.1 Global Myotonic Dystrophy Type 1 (DM1) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myotonic Dystrophy Type 1 (DM1) Revenue in 2023
3.5 Myotonic Dystrophy Type 1 (DM1) Key Players Head office and Area Served
3.6 Key Players Myotonic Dystrophy Type 1 (DM1) Product Solution and Service
3.7 Date of Enter into Myotonic Dystrophy Type 1 (DM1) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Myotonic Dystrophy Type 1 (DM1) Breakdown Data by Type
4.1 Global Myotonic Dystrophy Type 1 (DM1) Historic Market Size by Type (2019-2024)
4.2 Global Myotonic Dystrophy Type 1 (DM1) Forecasted Market Size by Type (2025-2030)
5 Myotonic Dystrophy Type 1 (DM1) Breakdown Data by Application
5.1 Global Myotonic Dystrophy Type 1 (DM1) Historic Market Size by Application (2019-2024)
5.2 Global Myotonic Dystrophy Type 1 (DM1) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Myotonic Dystrophy Type 1 (DM1) Market Size (2019-2030)
6.2 North America Myotonic Dystrophy Type 1 (DM1) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024)
6.4 North America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Myotonic Dystrophy Type 1 (DM1) Market Size (2019-2030)
7.2 Europe Myotonic Dystrophy Type 1 (DM1) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024)
7.4 Europe Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Size (2019-2030)
8.2 Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Size by Region (2019-2024)
8.4 Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Myotonic Dystrophy Type 1 (DM1) Market Size (2019-2030)
9.2 Latin America Myotonic Dystrophy Type 1 (DM1) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024)
9.4 Latin America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Size (2019-2030)
10.2 Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024)
10.4 Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Dyne
11.1.1 Dyne Company Detail
11.1.2 Dyne Business Overview
11.1.3 Dyne Myotonic Dystrophy Type 1 (DM1) Introduction
11.1.4 Dyne Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.1.5 Dyne Recent Development
11.2 Audentes
11.2.1 Audentes Company Detail
11.2.2 Audentes Business Overview
11.2.3 Audentes Myotonic Dystrophy Type 1 (DM1) Introduction
11.2.4 Audentes Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.2.5 Audentes Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Myotonic Dystrophy Type 1 (DM1) Introduction
11.3.4 Pfizer Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Vertex
11.4.1 Vertex Company Detail
11.4.2 Vertex Business Overview
11.4.3 Vertex Myotonic Dystrophy Type 1 (DM1) Introduction
11.4.4 Vertex Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.4.5 Vertex Recent Development
11.5 PepGen
11.5.1 PepGen Company Detail
11.5.2 PepGen Business Overview
11.5.3 PepGen Myotonic Dystrophy Type 1 (DM1) Introduction
11.5.4 PepGen Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.5.5 PepGen Recent Development
11.6 NeuBase Therapeutics
11.6.1 NeuBase Therapeutics Company Detail
11.6.2 NeuBase Therapeutics Business Overview
11.6.3 NeuBase Therapeutics Myotonic Dystrophy Type 1 (DM1) Introduction
11.6.4 NeuBase Therapeutics Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.6.5 NeuBase Therapeutics Recent Development
11.7 Lupin
11.7.1 Lupin Company Detail
11.7.2 Lupin Business Overview
11.7.3 Lupin Myotonic Dystrophy Type 1 (DM1) Introduction
11.7.4 Lupin Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.7.5 Lupin Recent Development
11.8 AMO Pharma
11.8.1 AMO Pharma Company Detail
11.8.2 AMO Pharma Business Overview
11.8.3 AMO Pharma Myotonic Dystrophy Type 1 (DM1) Introduction
11.8.4 AMO Pharma Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.8.5 AMO Pharma Recent Development
11.9 Expansion Therapeutics
11.9.1 Expansion Therapeutics Company Detail
11.9.2 Expansion Therapeutics Business Overview
11.9.3 Expansion Therapeutics Myotonic Dystrophy Type 1 (DM1) Introduction
11.9.4 Expansion Therapeutics Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.9.5 Expansion Therapeutics Recent Development
11.10 Harmony Biosciences
11.10.1 Harmony Biosciences Company Detail
11.10.2 Harmony Biosciences Business Overview
11.10.3 Harmony Biosciences Myotonic Dystrophy Type 1 (DM1) Introduction
11.10.4 Harmony Biosciences Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.10.5 Harmony Biosciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Exondys
Table 3. Key Players of Emflaza
Table 4. Key Players of Translarna
Table 5. Global Myotonic Dystrophy Type 1 (DM1) Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Myotonic Dystrophy Type 1 (DM1) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Myotonic Dystrophy Type 1 (DM1) Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Region (2019-2024)
Table 9. Global Myotonic Dystrophy Type 1 (DM1) Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Region (2025-2030)
Table 11. Myotonic Dystrophy Type 1 (DM1) Market Trends
Table 12. Myotonic Dystrophy Type 1 (DM1) Market Drivers
Table 13. Myotonic Dystrophy Type 1 (DM1) Market Challenges
Table 14. Myotonic Dystrophy Type 1 (DM1) Market Restraints
Table 15. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Players (2019-2024)
Table 17. Global Top Myotonic Dystrophy Type 1 (DM1) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myotonic Dystrophy Type 1 (DM1) as of 2023)
Table 18. Ranking of Global Top Myotonic Dystrophy Type 1 (DM1) Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Myotonic Dystrophy Type 1 (DM1) Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Myotonic Dystrophy Type 1 (DM1) Product Solution and Service
Table 22. Date of Enter into Myotonic Dystrophy Type 1 (DM1) Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Myotonic Dystrophy Type 1 (DM1) Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Type (2019-2024)
Table 26. Global Myotonic Dystrophy Type 1 (DM1) Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Type (2025-2030)
Table 28. Global Myotonic Dystrophy Type 1 (DM1) Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Application (2019-2024)
Table 30. Global Myotonic Dystrophy Type 1 (DM1) Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Application (2025-2030)
Table 32. North America Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030) & (US$ Million)
Table 47. Dyne Company Detail
Table 48. Dyne Business Overview
Table 49. Dyne Myotonic Dystrophy Type 1 (DM1) Product
Table 50. Dyne Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
Table 51. Dyne Recent Development
Table 52. Audentes Company Detail
Table 53. Audentes Business Overview
Table 54. Audentes Myotonic Dystrophy Type 1 (DM1) Product
Table 55. Audentes Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
Table 56. Audentes Recent Development
Table 57. Pfizer Company Detail
Table 58. Pfizer Business Overview
Table 59. Pfizer Myotonic Dystrophy Type 1 (DM1) Product
Table 60. Pfizer Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
Table 61. Pfizer Recent Development
Table 62. Vertex Company Detail
Table 63. Vertex Business Overview
Table 64. Vertex Myotonic Dystrophy Type 1 (DM1) Product
Table 65. Vertex Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
Table 66. Vertex Recent Development
Table 67. PepGen Company Detail
Table 68. PepGen Business Overview
Table 69. PepGen Myotonic Dystrophy Type 1 (DM1) Product
Table 70. PepGen Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
Table 71. PepGen Recent Development
Table 72. NeuBase Therapeutics Company Detail
Table 73. NeuBase Therapeutics Business Overview
Table 74. NeuBase Therapeutics Myotonic Dystrophy Type 1 (DM1) Product
Table 75. NeuBase Therapeutics Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
Table 76. NeuBase Therapeutics Recent Development
Table 77. Lupin Company Detail
Table 78. Lupin Business Overview
Table 79. Lupin Myotonic Dystrophy Type 1 (DM1) Product
Table 80. Lupin Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
Table 81. Lupin Recent Development
Table 82. AMO Pharma Company Detail
Table 83. AMO Pharma Business Overview
Table 84. AMO Pharma Myotonic Dystrophy Type 1 (DM1) Product
Table 85. AMO Pharma Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
Table 86. AMO Pharma Recent Development
Table 87. Expansion Therapeutics Company Detail
Table 88. Expansion Therapeutics Business Overview
Table 89. Expansion Therapeutics Myotonic Dystrophy Type 1 (DM1) Product
Table 90. Expansion Therapeutics Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
Table 91. Expansion Therapeutics Recent Development
Table 92. Harmony Biosciences Company Detail
Table 93. Harmony Biosciences Business Overview
Table 94. Harmony Biosciences Myotonic Dystrophy Type 1 (DM1) Product
Table 95. Harmony Biosciences Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
Table 96. Harmony Biosciences Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myotonic Dystrophy Type 1 (DM1) Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Type: 2023 VS 2030
Figure 3. Exondys Features
Figure 4. Emflaza Features
Figure 5. Translarna Features
Figure 6. Global Myotonic Dystrophy Type 1 (DM1) Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Application: 2023 VS 2030
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Home Care Case Studies
Figure 11. Myotonic Dystrophy Type 1 (DM1) Report Years Considered
Figure 12. Global Myotonic Dystrophy Type 1 (DM1) Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Myotonic Dystrophy Type 1 (DM1) Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Region: 2023 VS 2030
Figure 15. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Players in 2023
Figure 16. Global Top Myotonic Dystrophy Type 1 (DM1) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myotonic Dystrophy Type 1 (DM1) as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Myotonic Dystrophy Type 1 (DM1) Revenue in 2023
Figure 18. North America Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Myotonic Dystrophy Type 1 (DM1) Market Share by Country (2019-2030)
Figure 20. United States Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Myotonic Dystrophy Type 1 (DM1) Market Share by Country (2019-2030)
Figure 24. Germany Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Share by Region (2019-2030)
Figure 32. China Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Myotonic Dystrophy Type 1 (DM1) Market Share by Country (2019-2030)
Figure 40. Mexico Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Share by Country (2019-2030)
Figure 44. Turkey Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Dyne Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
Figure 47. Audentes Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
Figure 48. Pfizer Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
Figure 49. Vertex Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
Figure 50. PepGen Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
Figure 51. NeuBase Therapeutics Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
Figure 52. Lupin Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
Figure 53. AMO Pharma Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
Figure 54. Expansion Therapeutics Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
Figure 55. Harmony Biosciences Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
